These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
106 related articles for article (PubMed ID: 16807514)
1. Beta blockers in portal hypertension. Are they really a good option? López-Méndez E; Uribe M Ann Hepatol; 2006; 5(2):86-91. PubMed ID: 16807514 [TBL] [Abstract][Full Text] [Related]
3. The hemodynamic response to medical treatment of portal hypertension as a predictor of clinical effectiveness in the primary prophylaxis of variceal bleeding in cirrhosis. Merkel C; Bolognesi M; Sacerdoti D; Bombonato G; Bellini B; Bighin R; Gatta A Hepatology; 2000 Nov; 32(5):930-4. PubMed ID: 11050041 [TBL] [Abstract][Full Text] [Related]
11. Acute hemodynamic response to beta-blockers and prediction of long-term outcome in primary prophylaxis of variceal bleeding. Villanueva C; Aracil C; Colomo A; Hernández-Gea V; López-Balaguer JM; Alvarez-Urturi C; Torras X; Balanzó J; Guarner C Gastroenterology; 2009 Jul; 137(1):119-28. PubMed ID: 19344721 [TBL] [Abstract][Full Text] [Related]
12. Should we routinely measure portal pressure in patients with cirrhosis, using hepatic venous pressure gradient (HVPG) as guidance for prophylaxis and treatment of bleeding and re-bleeding? Yes! Merkel C; Montagnese S Eur J Intern Med; 2011 Feb; 22(1):1-4. PubMed ID: 21238883 [TBL] [Abstract][Full Text] [Related]
14. Preventing first variceal hemorrhage in cirrhosis. Albillos A J Clin Gastroenterol; 2007; 41 Suppl 3():S305-11. PubMed ID: 17975481 [TBL] [Abstract][Full Text] [Related]
15. Right atrial pressure is not adequate to calculate portal pressure gradient in cirrhosis: a clinical-hemodynamic correlation study. La Mura V; Abraldes JG; Berzigotti A; Erice E; Flores-Arroyo A; García-Pagán JC; Bosch J Hepatology; 2010 Jun; 51(6):2108-16. PubMed ID: 20512998 [TBL] [Abstract][Full Text] [Related]
16. Beta-blockers for prophylaxis of bleeding from esophageal varices in cirrhotic portal hypertension. Review of the literature. Zoller WG; Gross M Eur J Med Res; 1996 Jun; 1(9):407-16. PubMed ID: 9353240 [TBL] [Abstract][Full Text] [Related]
17. Randomised trial of nadolol alone or with isosorbide mononitrate for primary prophylaxis of variceal bleeding in cirrhosis. Gruppo-Triveneto per L'ipertensione portale (GTIP). Merkel C; Marin R; Enzo E; Donada C; Cavallarin G; Torboli P; Amodio P; Sebastianelli G; Sacerdoti D; Felder M; Mazzaro C; Beltrame P; Gatta A Lancet; 1996 Dec 21-28; 348(9043):1677-81. PubMed ID: 8973428 [TBL] [Abstract][Full Text] [Related]
18. Hemodynamic evaluation of the addition of isosorbide-5-mononitrate to nadolol in cirrhotic patients with insufficient response to the beta-blocker alone. Merkel C; Sacerdoti D; Bolognesi M; Enzo E; Marin R; Bombonato G; Angeli P; Gatta A Hepatology; 1997 Jul; 26(1):34-9. PubMed ID: 9214449 [TBL] [Abstract][Full Text] [Related]
19. The sixth Carlos E. Rubio Memorial Lecture. Prevention and treatment of variceal hemorrhage. Bosch J P R Health Sci J; 2000 Mar; 19(1):57-67. PubMed ID: 10761206 [TBL] [Abstract][Full Text] [Related]
20. Review: pharmacotherapeutic agents in the treatment of portal hypertension. Lebrec D J Gastroenterol Hepatol; 1997 Feb; 12(2):159-66. PubMed ID: 9083918 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]